Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thiéblemont, Pieternella J. Lugtenburg, Yasmin Karimi et al.|Leukemia|2024Cited by 132
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2Won-Seog Kim, Jan Walewski, Francesca Lim et al.|Blood|2022Cited by 28
P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2Jan Walewski, Won-Seog Kim, Tae Min Kim et al.|HemaSphere|2023Cited by 5
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 StudyElżbieta Iskierka‐Jazdzewska, Jan Walewski, Won Seog Kim et al.|Blood|2023Cited by 3